PAP
EWTX icon

Persistent Asset Partners’s Edgewise Therapeutics EWTX Stock Holding History

Persistent Asset Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-539
Closed -$591K – 847
2026
Q1 		$591K Buy
+539
New +$15.5K 0.22% 97
2025
Q2 		– Sell
-226
Closed -$75K – 200
2025
Q1 		$75K Buy
226
+126
+126% +$3.31K 0.06% 121
2024
Q4 		$60K Buy
+100
New +$3.18K 0.05% 112

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Persistent Asset Partners's EWTX Position: Q2 2026 in Review

Persistent Asset Partners increased its Edgewise Therapeutics (EWTX) stake by 591% in Q2 2026, buying an estimated $2.05M and bringing the position to 69,441 shares worth $2.82M. The position accounts for 0.84% of the portfolio, ranked #23.

Persistent Asset Partners first reported a position in EWTX in Q4 2024 and has held it in 4 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Persistent Asset Partners held 69,441 shares of Edgewise Therapeutics worth $2.82M as of Q2 2026.
  • Persistent Asset Partners bought 59,388 Edgewise Therapeutics shares in Q2 2026, an estimated $2.05M.
  • Edgewise Therapeutics made up 0.84% of Persistent Asset Partners's portfolio in Q2 2026, its #23 holding.
  • Persistent Asset Partners first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.